Bile acid detoxification by nuclear receptor-mediated CYP3A regulation
Bile acid detoxification by nuclear receptor-mediated CYP3A regulation
批准号:
nhmrc : 153890
负责人:
Prof Christopher Liddle
金额:
$13.1万
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2001
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2001-01-01 至 2003-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Liver diseases in which there is obstruction to bile flow (cholestatic liver diseases) can lead to liver failure, liver cirrhosis as well as a diminished quality of life. Patients suffer from severe itching which may prove difficult to control. It is thought that many of these adverse effects of obstructed bile flow are due to the retention of a component of bile, called bile acids, within the body. Bile acids are detergent-like compounds formed from cholesterol. Some bile acids are highly toxic and cause the death of cells in the liver if their concentration becomes too high. Evidence has emerged that the body has control mechanisms to try and combat rising levels of bile acids in cholestatic liver diseases. One such mechanism, which is the subject of this application, is the metabolism of bile acids to less toxic forms, by a process called hydroxylation. A particular class of liver enzymes, known as cytochromes P450 CYP3As, appear to mediate these hydroxylation reactions. Liver cytochrome P450 enzymes are important to medicine in areas as broad as drug breakdown, steroid hormone regulation and the formation or elimination of cancer causing chemicals. These enzymes are present in high concentration in the human liver, but the factors governing how much of these enzymes are produced have been poorly understood. The present projects builds on discoveries concerning the regulation of cytochrome P450 enzymes made by our group over the last few years, including an in-depth understanding of the way the production of CYP3As are increased by some drugs. We intend to determine the mechanism by which bile acids increase the level of CYP3A enzymes are how effective these enzymes are in hydroxylating bile acids. An understanding of these issues will allow us to better manage patents with cholestatic liver diseases and develop new strategies for treating these diseases, for example, development of novel drugs that increase bile acid hydroxylation in the liver.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MERTK receptor tyrosine kinase: A novel therapeutic target for liver fibrosis
-
批准号:nhmrc : GNT1107178
-
项目类别:Project Grants
-
资助金额:$87.1万
-
财政年份:2016
-
负责人:Prof Christopher Liddle
-
依托单位:
MERTK receptor tyrosine kinase: A novel therapeutic target for liver fibrosis
-
批准号:nhmrc : 1107178
-
项目类别:Project Grants
-
资助金额:$59.92万
-
财政年份:2016
-
负责人:Prof Christopher Liddle
-
依托单位:
How does dietary cholesterol induce non-alcoholic steatohepatitis?
-
批准号:nhmrc : 1108422
-
项目类别:Project Grants
-
资助金额:$55.23万
-
财政年份:2016
-
负责人:Prof Christopher Liddle
-
依托单位:
Molecular mechanisms of human cytochrome P450 CYP3A4 gene regulation
-
批准号:nhmrc : 107245
-
项目类别:NHMRC Project Grants
-
资助金额:$13.07万
-
财政年份:2000
-
负责人:Prof Christopher Liddle
-
依托单位:
国内基金
海外基金
登录
查看更多内容
棕榈酸Palmitic acid通过靶向JAK-STAT通路促进致病性Th17细胞分化在儿童性系统性红斑狼疮中的作用及机制研究
-
批准号:2026JJ81716
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:唐金玲
-
依托单位:
基于F/IGF1R/PKC ζ 通路研究夏枯草中
Mesonolic acid B抑制RSV感染性肺炎的
作用机制
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:唐维
-
依托单位:
Quinic acid通过抑制肠道菌群代谢产物脱氧胆酸调节巨噬细胞M1向M2极化改善动脉粥样硬化的机制研究
-
批准号:2025JJ80556
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:吴鹏翠
-
依托单位:
脂肪酸α-dimorphecolicacid抑制NF-κB信号介导的小胶质细胞炎症缓解多发性硬化的免疫代谢调控机制研究
-
批准号:QN25H310018
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:杨帆
-
依托单位:
巨噬细胞来源代谢物suberic acid抑制蜕膜早衰防治早产的作用机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:梅又文
-
依托单位:
色氨酸代谢产物Kynurenic Acid在脓毒症肠损伤中的诊断价值及其机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:5.0万元
-
批准年份:2024
-
负责人:陈慧
-
依托单位:
α-酮戊二酸调控ACMSD介导犬尿氨酸通路代谢重编程在年龄相关性听力损失中的作用及机制研究
-
批准号:82371150
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:侯书乐
-
依托单位:
肠道菌群介导的脱氧胆酸激活S1PR2/NLRP3/IL-1β通路在炎症性肠病合并艰难梭菌感染中的致病机制研究
-
批准号:82372306
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:彭奕冰
-
依托单位:
“肠—肝轴”PPARα/CYP8B1胆汁酸合成信号通路在减重手术改善糖脂代谢中的作用与机制
-
批准号:82370902
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:田景琰
-
依托单位:
转运蛋白RCP调控巨噬细胞脂肪酸氧化参与系统性红斑狼疮发病的机制研究
-
批准号:82371798
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:叶俊娜
-
依托单位: